{"product_id":"veterinary-psychopharmacology-isbn-9781119226222","title":"Veterinary Psychopharmacology","description":"\u003cp\u003e\u003cb\u003eOffers an updated second edition of the comprehensive reference on the use of drugs for veterinary mental health care and behavior modification\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThis fully revised Second Edition of \u003ci\u003eVeterinary Psychopharmacology \u003c\/i\u003eoffers an authoritative reference to the drugs prescribed to treat psychiatric, psychological, and behavioral disorders in pets. Designed to be an accessible resource, the text is divided into sections on psychopharmacologic principles and clinical psychopharmacology. Comprehensive in scope, the book contains detailed information on pharmacologic intervention for pet mental health and behavior issues, offers thorough explanations of options, and explores why a particular drug should be prescribed and why it works.\u003c\/p\u003e \u003cp\u003eUpdated to include the recent advances in psychopharmacology for pets, the Second Edition includes new chapters that cover the principles of psychopharmacology, miscellaneous serotonergic agents, anticonvulsants and mood stabilizers, sympatholytic agents, and NMDA antagonists. In addition, the text explains the drug options, including all the information necessary to correct dysfunctions in the brain’s chemistry through pharmacologic treatment. This important resource:\u003c\/p\u003e \u003cul\u003e \u003cli\u003ePresents an updated and comprehensive resource for pharmacologic treatments for pet, equine, and zoo animal psychiatric disorders and behavior problems\u003c\/li\u003e \u003cli\u003eContains in-depth information on drugs that promote neurochemical changes that will alter the mood, emotional state, reactivity, and behavior of the patient, including prescribing options and mechanisms of action\u003c\/li\u003e \u003cli\u003eIncludes new chapters on the principles of psychopharmacology, miscellaneous serotonergic agents, mood stabilizers, sympatholytic agents, and NMDA antagonists\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWritten for veterinarians, veterinary behaviorists, and veterinary students, the updated second edition of \u003ci\u003eVeterinary Psychopharmacology\u003c\/i\u003e is a complete source for current knowledge on pharmacologic behavior modification.\u003cbr\u003e\u003cbr\u003e“Overall, this book packs a substantial amount of useful data into approximately 300 pages. The scope of the book is comprehensive and may include more in-depth information than casual prescribers seek, but it will be a good resource for the practitioners who are interested in immersing themselves into veterinary psychopharmacology.” - JAVMA Vol 255 No. 6\u003c\/p\u003e \u003cp\u003eContributors xxi\u003c\/p\u003e \u003cp\u003ePreface xxiii\u003c\/p\u003e \u003cp\u003eAcknowledgments xxv\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Principles of Veterinary Psychopharmacology 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 General Principles of Psychopharmacology 3\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eThomas F. Murray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eDrug Action 3\u003c\/p\u003e \u003cp\u003eDose Dependence of Drug Interaction with Receptors 4\u003c\/p\u003e \u003cp\u003eStructural Features of the Central Nervous System (CNS) and Neurotransmission 5\u003c\/p\u003e \u003cp\u003eBiogenic Amine Neurotransmitters and Affective Disorders 8\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Amino Acid Neurotransmitters: Glutamate, GABA, and the Pharmacology of Benzodiazepines 11\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eThomas F. Murray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 11\u003c\/p\u003e \u003cp\u003eGlutamatergic Synapses 11\u003c\/p\u003e \u003cp\u003ePharmacology of Ketamine and Tiletamine 14\u003c\/p\u003e \u003cp\u003eGABAergic Synapses 15\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Biogenic Amine Neurotransmitters: Serotonin 21\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eThomas F. Murray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 21\u003c\/p\u003e \u003cp\u003eThe Biogenic Amines 21\u003c\/p\u003e \u003cp\u003eSerotonin 22\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Biogenic Amine Transmitters: Acetylcholine, Norepinephrine, and Dopamine 29\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eThomas F. Murray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAcetylcholine 29\u003c\/p\u003e \u003cp\u003eNorepinephrine 32\u003c\/p\u003e \u003cp\u003eDopamine 37\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Neuropeptides: Opioids and Oxytocin 43\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eThomas F. Murray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 43\u003c\/p\u003e \u003cp\u003eEndogenous Opioid Peptides 43\u003c\/p\u003e \u003cp\u003eOxytocin 47\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Practice of Veterinary Psychopharmacology 51\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Introduction to Clinical Psychopharmacology for Veterinary Medicine 53\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSharon L. Crowell‐Davis and Leticia Mattos de Souza Dantas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 53\u003c\/p\u003e \u003cp\u003ePrescribing in the United States: The Animal Medicinal Drug Use Clarification Act (AMDUCA 1994) 54\u003c\/p\u003e \u003cp\u003eCost 55\u003c\/p\u003e \u003cp\u003eDrug Selection 56\u003c\/p\u003e \u003cp\u003eMedicating the Patient 57\u003c\/p\u003e \u003cp\u003eCompetition Animals 58\u003c\/p\u003e \u003cp\u003eTaking the Behavioral History 58\u003c\/p\u003e \u003cp\u003eThe Behavioral Exam 63\u003c\/p\u003e \u003cp\u003eDuration of Treatment 63\u003c\/p\u003e \u003cp\u003eLimitations 64\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Benzodiazepines 67\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLeticia Mattos de Souza Dantas and Sharon L. Crowell-Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAction 67\u003c\/p\u003e \u003cp\u003eOverview of Indications 67\u003c\/p\u003e \u003cp\u003eContraindications, Side Effects, and Adverse Events 69\u003c\/p\u003e \u003cp\u003eOverdose 69\u003c\/p\u003e \u003cp\u003eClinical Guidelines 69\u003c\/p\u003e \u003cp\u003eSpecific Medications 71\u003c\/p\u003e \u003cp\u003eI. Alprazolam 71\u003c\/p\u003e \u003cp\u003eII. Chlordiazepoxide HC1 73\u003c\/p\u003e \u003cp\u003eIV. Clorazepate Dipotassium 78\u003c\/p\u003e \u003cp\u003eV. Diazepam 80\u003c\/p\u003e \u003cp\u003eVI. Flurazepam Hydrochloride 86\u003c\/p\u003e \u003cp\u003eVII. Lorazepam 87\u003c\/p\u003e \u003cp\u003eVIII. Oxazepam 89\u003c\/p\u003e \u003cp\u003eIX. Triazolam 91\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Selective Serotonin Reuptake Inhibitors 103\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eNiwako Ogata, Leticia Mattos de Souza Dantas, and Sharon L. Crowell‐Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAction 103\u003c\/p\u003e \u003cp\u003eOverview of Indications 103\u003c\/p\u003e \u003cp\u003eContraindications, Side Effects, and Adverse Events 104\u003c\/p\u003e \u003cp\u003eAdverse Drug Interactions 104\u003c\/p\u003e \u003cp\u003eOverdose 105\u003c\/p\u003e \u003cp\u003eClinical Guidelines 105\u003c\/p\u003e \u003cp\u003eSpecific Medications 106\u003c\/p\u003e \u003cp\u003eI. Citalopram Hydrobromide 106\u003c\/p\u003e \u003cp\u003eII. Fluoxetine Hydrochloride 108\u003c\/p\u003e \u003cp\u003eIII. Fluvoxamine 115\u003c\/p\u003e \u003cp\u003eIV. Paroxetine Hydrochloride 117\u003c\/p\u003e \u003cp\u003eV. Sertraline Hydrochloride 119\u003c\/p\u003e \u003cp\u003eVI. Escitalopram Oxalate 122\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Miscellaneous Serotonergic Agents 129\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLeticia Mattos de Souza Dantas and Sharon L. Crowell‐Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 129\u003c\/p\u003e \u003cp\u003eAzapirones 129\u003c\/p\u003e \u003cp\u003eAction 129\u003c\/p\u003e \u003cp\u003eOverview of Indications 129\u003c\/p\u003e \u003cp\u003eContraindications, Side Effects, and Adverse Events 129\u003c\/p\u003e \u003cp\u003eAdverse Drug Interactions 129\u003c\/p\u003e \u003cp\u003eOverdose 129\u003c\/p\u003e \u003cp\u003eClinical Guidelines 129\u003c\/p\u003e \u003cp\u003eSpecific Medications 130\u003c\/p\u003e \u003cp\u003eI. Buspirone 130\u003c\/p\u003e \u003cp\u003eI. Trazodone Hydrochloride 135\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Anticonvulsants and Mood Stabilizers 147\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSharon L. Crowell‐Davis, Mami Irimajiri, and Leticia Mattos de Souza Dantas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAction 147\u003c\/p\u003e \u003cp\u003eOverview of Indications 148\u003c\/p\u003e \u003cp\u003eClinical Guidelines 148\u003c\/p\u003e \u003cp\u003eSpecific Medications 148\u003c\/p\u003e \u003cp\u003eI. Carbamazepine 148\u003c\/p\u003e \u003cp\u003eII. Gabapentin 149\u003c\/p\u003e \u003cp\u003eIII. Pregabalin 152\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Sympatholytic Agents 157\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eNiwako Ogata and Leticia Mattos de Souza Dantas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAction 157\u003c\/p\u003e \u003cp\u003eOverview of Indications 157\u003c\/p\u003e \u003cp\u003eContraindications, Side Effects, and Adverse Events 158\u003c\/p\u003e \u003cp\u003eOverdose 159\u003c\/p\u003e \u003cp\u003eClinical Guidelines 159\u003c\/p\u003e \u003cp\u003eSpecific Medications 160\u003c\/p\u003e \u003cp\u003eI. Clonidine 160\u003c\/p\u003e \u003cp\u003eII. Detomidine 161\u003c\/p\u003e \u003cp\u003eIII. Dexmedetomidine 163\u003c\/p\u003e \u003cp\u003eIV. Propranolol 165\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 N‐Methyl‐D‐Aspartate (NMDA) Receptor Antagonists 171\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eNiwako Ogata and Leticia Mattos de Souza Dantas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAction 171\u003c\/p\u003e \u003cp\u003eOverview of Indications 172\u003c\/p\u003e \u003cp\u003eContraindications\/ Side Effects, and Adverse Events 172\u003c\/p\u003e \u003cp\u003eClinical Guidelines 173\u003c\/p\u003e \u003cp\u003eSpecific Medications 173\u003c\/p\u003e \u003cp\u003eI. Dextromethorphan 173\u003c\/p\u003e \u003cp\u003eII. Amantadine 175\u003c\/p\u003e \u003cp\u003eIII. Memantine 176\u003c\/p\u003e \u003cp\u003eIV. Huperzine A 179\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Monoamine Oxidase Inhibitors 185\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLeticia Mattos de Souza Dantas and Sharon L. Crowell‐Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAction 185\u003c\/p\u003e \u003cp\u003eOverview of Indications 186\u003c\/p\u003e \u003cp\u003eSpecific Medications 186\u003c\/p\u003e \u003cp\u003eI. Selegiline Hydrochloride 186\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Antipsychotics 201\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLynne Seibert and Sharon Crowell‐Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 201\u003c\/p\u003e \u003cp\u003eAction 201\u003c\/p\u003e \u003cp\u003eOverview of Indications 202\u003c\/p\u003e \u003cp\u003eGeneral Pharmacokinetics 203\u003c\/p\u003e \u003cp\u003eContraindications, Side Effects, and Adverse Events 203\u003c\/p\u003e \u003cp\u003eOverdose 203\u003c\/p\u003e \u003cp\u003eClinical Guidelines 204\u003c\/p\u003e \u003cp\u003eSpecific Medications 204\u003c\/p\u003e \u003cp\u003eI. Acepromazine Maleate 204\u003c\/p\u003e \u003cp\u003eII. Azaperone 206\u003c\/p\u003e \u003cp\u003eIII. Chlorpromazine 206\u003c\/p\u003e \u003cp\u003eIV. Clozapine 207\u003c\/p\u003e \u003cp\u003eV. Fluphenazine 208\u003c\/p\u003e \u003cp\u003eVI. Haloperidol 209\u003c\/p\u003e \u003cp\u003eVII. Pimozide 210\u003c\/p\u003e \u003cp\u003eVIII. Promazine 211\u003c\/p\u003e \u003cp\u003eIX. Sulpiride 211\u003c\/p\u003e \u003cp\u003eX. Thioridazine 212\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 CNS Stimulants 217\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSharon L. Crowell‐Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAction 217\u003c\/p\u003e \u003cp\u003eOverview of Indications 217\u003c\/p\u003e \u003cp\u003eContraindications, Side Effects, and Adverse Events 217\u003c\/p\u003e \u003cp\u003eAdverse Drug Interactions 217\u003c\/p\u003e \u003cp\u003eOverdose 217\u003c\/p\u003e \u003cp\u003eClinical Guidelines 218\u003c\/p\u003e \u003cp\u003eSpecific Medications 219\u003c\/p\u003e \u003cp\u003eI. Amphetamine 219\u003c\/p\u003e \u003cp\u003eII. Atomoxetine HCl 221\u003c\/p\u003e \u003cp\u003eIII. Methylphenidate Hydrochloride 223\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Tricyclic Antidepressants 231\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSharon L. Crowell‐Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAction 231\u003c\/p\u003e \u003cp\u003eOverview of Indications 231\u003c\/p\u003e \u003cp\u003eContraindications, Side Effects, and Adverse Events 232\u003c\/p\u003e \u003cp\u003eAdverse Drug Interactions 232\u003c\/p\u003e \u003cp\u003eOverdose 232\u003c\/p\u003e \u003cp\u003eDiscontinuation 233\u003c\/p\u003e \u003cp\u003eClinical Guidelines 233\u003c\/p\u003e \u003cp\u003eSpecific Medications 233\u003c\/p\u003e \u003cp\u003eI. Amitriptyline 233\u003c\/p\u003e \u003cp\u003eII. Clomipramine Hydrochloride 236\u003c\/p\u003e \u003cp\u003eIII. Desipramine 243\u003c\/p\u003e \u003cp\u003eIV. Doxepin 244\u003c\/p\u003e \u003cp\u003eV. Imipramine 246\u003c\/p\u003e \u003cp\u003eVI. Nortriptyline 248\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Opioids and Opioid Antagonists 257\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLeticia Mattos de Souza Dantas and Sharon L. Crowell‐Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAction 257\u003c\/p\u003e \u003cp\u003eOverview of Indications 257\u003c\/p\u003e \u003cp\u003eContraindications, Side Effects, and Adverse Events 258\u003c\/p\u003e \u003cp\u003eClinical Guidelines 258\u003c\/p\u003e \u003cp\u003eSpecific Medications 258\u003c\/p\u003e \u003cp\u003eI. Nalmefene 258\u003c\/p\u003e \u003cp\u003eII. Naloxone HCl 260\u003c\/p\u003e \u003cp\u003eIII. Naltrexone Hydrochloride 261\u003c\/p\u003e \u003cp\u003eIV. Pentazocine 264\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Hormones 269\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSharon L. Crowell‐Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 269\u003c\/p\u003e \u003cp\u003eOxytocin 270\u003c\/p\u003e \u003cp\u003eClinical Pharmacology 270\u003c\/p\u003e \u003cp\u003eIndications 270\u003c\/p\u003e \u003cp\u003eSide Effects 270\u003c\/p\u003e \u003cp\u003eDoses in Nonhuman Animals 270\u003c\/p\u003e \u003cp\u003eEffects Documented in Nonhuman Animals 270\u003c\/p\u003e \u003cp\u003eProgestins 270\u003c\/p\u003e \u003cp\u003eAction 270\u003c\/p\u003e \u003cp\u003eOverview of Indications 271\u003c\/p\u003e \u003cp\u003eContraindications, Side Effects, and Adverse Events 271\u003c\/p\u003e \u003cp\u003eOverdose 271\u003c\/p\u003e \u003cp\u003eClinical Guidelines 272\u003c\/p\u003e \u003cp\u003eSpecific Medications 272\u003c\/p\u003e \u003cp\u003eI. Medroxyprogesterone Acetate (MPA) 272\u003c\/p\u003e \u003cp\u003eII. Megestrol Acetate 273\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Combinations 281\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLeticia Mattos de Souza Dantas, Sharon L. Crowell‐Davis, and Niwako Ogata\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 281\u003c\/p\u003e \u003cp\u003eOverview of Drug Augmentation 281\u003c\/p\u003e \u003cp\u003ePotentially Beneficial Combinations 282\u003c\/p\u003e \u003cp\u003eAdverse Interactions and Contraindications 283\u003c\/p\u003e \u003cp\u003eChanging and Weaning Patients off Medications 285\u003c\/p\u003e \u003cp\u003eCytochrome P450 (CYP) 285\u003c\/p\u003e \u003cp\u003eInteractions That Can Affect Dosing 285\u003c\/p\u003e \u003cp\u003eAlgorithms: Possible Future Direction 286\u003c\/p\u003e \u003cp\u003eConclusion 288\u003c\/p\u003e \u003cp\u003eIndex 291\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eThe Authors\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003cb\u003eThe Editors\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003cb\u003eSharon L. Crowell-Davis,\u003c\/b\u003e DVM, PhD, DACVB, is a Professor of Behavioral Medicine in the Department of Veterinary Biosciences and Diagnostic Imaging, College of Veterinary Medicine, the University of Georgia in Athens, Georgia, USA. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eThomas F. Murray,\u003c\/b\u003e PhD, is a Professor of Pharmacology and Provost of Creighton University in Omaha, Nebraska, USA. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eLeticia Mattos de Souza Dantas,\u003c\/b\u003e DVM, MS, PhD, DACVB is a Clinical Assistant Professor of Behavioral Medicine at the University of Georgia Veterinary Teaching Hospital and the Department of Veterinary Biosciences and Diagnostic Imaging at the College of Veterinary Medicine, University of Georgia in Athens, Georgia, USA. She is also the Director and Co-founder of ZooPsych, Inc., a consultancy in Clinical Behavioral Medicine \u0026amp; Therapy in Georgia, USA.   \u003c\/p\u003e\u003cp\u003e\u003cb\u003eOffers an updated second edition of the comprehensive reference on the use of drugs for veterinary mental health care and behavior modification\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eThis fully revised Second Edition of \u003ci\u003eVeterinary Psychopharmacology\u003c\/i\u003e offers an authoritative reference to the drugs prescribed to treat psychiatric, psychological, and behavioral disorders in pets. Designed to be an accessible resource, the text is divided into sections on psychopharmacologic principles and clinical psychopharmacology. Comprehensive in scope, the book contains detailed information on pharmacologic intervention for pet mental health and behavior issues, offers thorough explanations of options, and explores why a particular drug should be prescribed and why it works. \u003c\/p\u003e\u003cp\u003eUpdated to include the recent advances in psychopharmacology for pets, the Second Edition includes new chapters that cover the principles of psychopharmacology, miscellaneous serotonergic agents, anticonvulsants and mood stabilizers, sympatholytic agents, and NMDA antagonists. In addition, the text explains the drug options, including all the information necessary to correct dysfunctions in the brain's chemistry through pharmacologic treatment. This important resource: \u003c\/p\u003e\u003cul\u003e \u003cli\u003ePresents an updated and comprehensive resource for pharmacologic treatments for pet, equine, and zoo animal psychiatric disorders and behavior problems\u003c\/li\u003e \u003cli\u003eContains in-depth information on drugs that promote neurochemical changes that will alter the mood, emotional state, reactivity, and behavior of the patient, including prescribing options and mechanisms of action\u003c\/li\u003e \u003cli\u003eIncludes new chapters on the principles of psychopharmacology, miscellaneous serotonergic agents, mood stabilizers, sympatholytic agents, and NMDA antagonists\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWritten for veterinarians, veterinary behaviorists, and veterinary students, the updated second edition of \u003ci\u003eVeterinary Psychopharmacology\u003c\/i\u003e is a complete source for current knowledge on pharmacologic behavior modification.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47990451732709,"sku":"NP9781119226222","price":131.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119226222.jpg?v=1761787885","url":"https:\/\/k12savings.com\/products\/veterinary-psychopharmacology-isbn-9781119226222","provider":"K12savings","version":"1.0","type":"link"}